A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Key claim: A Phase 1/2 dose-escalation trial is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral nuvisertib (TP-3654), a PIM kinase inhibitor, in patients with intermediate or high-risk primary or secondary myelofibrosis.
Abstract
This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
Why this matters
Nuvisertib (TP-3654) introduces PIM kinase inhibition as a mechanistically distinct therapeutic axis for myelofibrosis, separate from JAK inhibitors and the other novel pathway-targeted agents (BET, LSD1, HDAC, RSK1) being explored in this area. As a Phase 1/2 dose-escalation study, this is early signal-finding evidence that will define safety, tolerability, and pharmacodynamic biomarkers needed to position PIM inhibition — alone or in combination — within the expanding MF treatment landscape.